Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (1516)	5/14/2003 8:19:07 AM
From: tom pope	Read Replies (1) \| Respond to of 3044

Here's Briefing's take: 06:06 ET MLNM Millennium Pharma receives rapid approval for Velcade (12.49) Analysts are positively surprised after Millennium Pharma's surprise approval for Velcade for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The approval comes approx 1.5 quarters ahead of expectations and with a broader label than the majority of analyst community had expected possibly doubling the revenue potential. This news can be viewed as a considerable negative for Celgene (CELG) whose lead drug Thalomid (not approved for MM) will face strong competition from Velcade.

To: dalroi who wrote (1516)	5/14/2003 9:48:11 AM
From: Robohogs	Respond to of 3044

No way this helps SEPR as the MLNM drug is for life threatening illnesses and the SEPR drug is for a me-too drug for a soon to be OTC market, at least in the FDA's eyes. Jon

To: dalroi who wrote (1516)	5/14/2003 7:05:41 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3044

Stefaan, <<perhaps we should start looking at fda postponed drugs like the one from prcs/sepr.>> There is no white and black contrast. Every NDA, every candidate is new story. FDA is getting seriously down to basic business and that is good for whole pharma industry. Velcade approval was clear cut. <<if velcade is now approived doesnt that put mlnm in a beter bargaining positon concerning partnership or is this going to be announced before the open tomorrow>> I think that partner should be pleased with Velcade initial label. More close to second line than third line MM therapy. Also, FDA requested comparing Velcade to standard therapy (not Dexa), so this should means that FDA is aware of moving V toward first line therapy. Miljenko PS: You can always buy calls back, as I did with my ABGX hedge after Iressa approval.